Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 3/20 | 0.55 |
| ▸ | CES2 | O00748 | 2/20 | 0.52 |
| ▸ | CES1 | P23141 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | STAT6 | P42226 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | THRA | P10827 | 6/20 | 0.42 |
| ▸ | THRB | P10828 | 6/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | GSR | P00390 | 2/20 | 0.41 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3220179 | 0.89 | ACKR3 (0.51) | ACKR3CES2CES1ALDH1A1THRA | |
| SCHEMBL12185681 | 0.87 | ACKR3 (0.70) | ACKR3CES2CES1ALDH1A1CYP1A2 | |
| SCHEMBL12781706 | 0.85 | ACKR3 (0.50) | ACKR3ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL955792 | 0.79 | CTNNB1 (0.51) | ACKR3CES2CES1ALDH1A1CYP1A2 | |
| SCHEMBL30200290 | 0.79 | CTNNB1 (0.51) | ACKR3CES2CES1ALDH1A1CYP1A2 | |
| SCHEMBL28062364 | 0.78 | HTR7 (0.59) | ACKR3CES2CES1ALDH1A1DRD2 | |
| SCHEMBL5084694 | 0.77 | CES2 (0.57) | ACKR3CES2CES1ALDH1A1CYP1A2 | |
| SCHEMBL954719 | 0.77 | CES2 (0.61) | CES2CES1ALDH1A1RIPK1 | |
| SCHEMBL31130589 | 0.77 | CES2 (0.61) | CES2CES1ALDH1A1RIPK1 | |
| SCHEMBL18884981 | 0.77 | CES2 (0.52) | ACKR3CES2CES1ALDH1A1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105330595-B | pyridine derivatives and their use as antimycobacterial agents | 上海嘉坦医药科技有限公司 | 2019-12-10 | — | — | CN | disclosed |
| EP-3170810-B1 | PYRIDINE DERIVATIVES AND ANTI-MYCOBACTERIAL USE THEREOF | CISEN PHARMACEUTICAL CO LTD (CN) | 2018-09-19 | — | — | EP | disclosed |
| US-9878982-B2 | Pyridine derivatives and anti-mycobacterial use thereof | CISEN PHARMACEUTICAL CO., LTD. (CN) | 2018-01-30 | — | — | US | disclosed |
| US-9878982-B2 | Pyridine derivatives and anti-mycobacterial use thereof | CISEN PHARMACEUTICAL CO., LTD. (CN) | 2018-01-30 | — | — | US | disclosed |
| US-9878982-B2 | Pyridine derivatives and anti-mycobacterial use thereof | CISEN PHARMACEUTICAL CO., LTD. (CN) | 2018-01-30 | — | — | US | disclosed |
| US-20170174628-A1 | PYRIDINE DERIVATIVES AND ANTI-MYCOBACTERIAL USE THEREOF | CISEN PHARMACEUTICAL CO., LTD. (CN) | 2017-06-22 | — | — | US | disclosed |
| US-20170174628-A1 | PYRIDINE DERIVATIVES AND ANTI-MYCOBACTERIAL USE THEREOF | CISEN PHARMACEUTICAL CO., LTD. (CN) | 2017-06-22 | — | — | US | disclosed |
| US-20170174628-A1 | PYRIDINE DERIVATIVES AND ANTI-MYCOBACTERIAL USE THEREOF | CISEN PHARMACEUTICAL CO., LTD. (CN) | 2017-06-22 | — | — | US | disclosed |
| EP-3170810-A1 | PYRIDINE DERIVATIVES AND ANTI-MYCOBACTERIAL USE THEREOF | Cisen Pharmaceutical Co. Ltd. (CN) | 2017-05-24 | — | — | EP | disclosed |
| EP-3170810-A1 | PYRIDINE DERIVATIVES AND ANTI-MYCOBACTERIAL USE THEREOF | Cisen Pharmaceutical Co. Ltd. (CN) | 2017-05-24 | — | — | EP | disclosed |
| WO-2016008381-A1 | PYRIDINE DERIVATIVES AND ANTI-MYCOBACTERIAL USE THEREOF | 辰欣药业股份有限公司 | 2016-01-21 | — | — | WO | disclosed |
| EP-2301544-B1 | Quinoline derivatives as intermediates to mycobacterial inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2012-09-19 | — | — | EP | disclosed |
| EP-2301544-A1 | Quinoline derivatives as intermediates to mycobacterial inhibitors | Janssen Pharmaceutica N.V. (BE) | 2011-03-30 | — | — | EP | disclosed |
| EP-1527050-B1 | QUINOLINE DERIVATIVES AND THEIR USE AS MYCOBACTERIAL INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-07 | — | — | EP | disclosed |
| US-7498343-B2 | Quinolines; 1-(6-bromo-2-methoxy-quinolin-3-yl)-4-dimethylamino-2-naphthalen-1-yl-1-phenyl-butan-2-ol; Mycobacterium tuberculosis, M. bovis, M. avium and M. marinum; reduces the total length of treatment and the frequency of drug administration; multi-drug and antibiotic resistance | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-03 | — | — | US | disclosed |
| US-20050148581-A1 | Novel mycobacterial inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-07-07 | — | — | US | disclosed |
| EP-1527050-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS MYCOBACTERIAL INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-05-04 | — | — | EP | disclosed |
| WO-2004011436-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS MYCOBACTERIAL INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148581-A1 | Novel mycobacterial inhibitors | NDUFB5, MT-ND1, NDUFB7 | ACKR3 4242/4885CES2 4192/4885CES1 2409/4885 |
| US-20170174628-A1 | PYRIDINE DERIVATIVES AND ANTI-MYCOBACTERIAL USE THEREOF | ME3, SSBP1, MDH2 | ACKR3 2621/4885CES2 3695/4885CES1 4237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.